Melanoma-associated antigen 3 (MAGE-A3) (MAGE-A3)

Melanoma-associated antigen 3 (MAGE-A3) is a member of the MAGE-A family of cancer-testis antigens (CTAs), which are typically expressed only in the immune-privileged germ cells of the testis and placenta but are aberrantly overexpressed in various malignancies [1, 4, 5]. Biologically, MAGE-A3 acts as a molecular scaffold that enhances the activity of E3 ubiquitin ligases, such as TRIM28, to facilitate the degradation of tumor suppressors like p53 and AMPK [1, 10]. This mechanism promotes tumor cell survival, proliferation, and resistance to apoptosis, contributing to its role as a driver of oncogenesis and a marker of poor prognosis in cancers such as melanoma and non-small cell lung cancer [10, 12]. Due to its tumor-specific expression, MAGE-A3 has been a major target for cancer immunotherapies, including recombinant protein vaccines (e.g., GSK's MAGE-A3 + AS15) and adoptive T-cell therapies using engineered T-cell receptors (TCR-T) [15, 16, 19]. However, clinical development has faced significant hurdles, including the failure of large-scale phase III trials and severe off-target toxicities [14, 16]. Specifically, affinity-enhanced TCRs have demonstrated fatal cross-reactivity with the muscle protein titin in the heart and homologous proteins like MAGE-A12 or EPS8L2 in the central nervous system, highlighting the critical need for high specificity in targeting this intracellular antigen [19, 20].

Other names

MAGE3MAGE-3Cancer/testis antigen 1.3CT1.3Antigen MZ2-DHIP8HYPD

Immunotherapy including antigen-specific vaccination, adoptive T-cell therapy (TCR-T), and oncolytic virotherapy designed to induce or provide a T-cell mediated immune response against MAGE-A3-expressing cells.